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Clinical Remission of Delta-Aminolevulinic 
Acid Dehydratase Deficiency Through 
Suppression of Erythroid Heme Synthesis
Rochus A. Neeleman ,1 Eduard J. van Beers,2 Edith C. Friesema,1 Rita Koole-Lesuis,1 Willem L. van der Pol,3 J.H. Paul Wilson,1 
and Janneke G. Langendonk1
Delta-aminolevulinic acid dehydratase-porphyria (ADP) is an autosomal recessive disorder of heme biosynthesis, caused by delta-amino-
levulinic acid dehydratase deficiency (ALAD).(1) We 
report an important change in pathophysiological con-
cepts and subsequent therapeutic options for patients 
with ADP, based on a review of previous cases and the 
treatment effects in a reported case.
Case Report
A Dutch patient was admitted 2 days after birth, 
with sudden onset of tetraplegia and respiratory insuf-
ficiency. During this episode the etiology remained 
unresolved. He partially recovered, and his childhood 
was marked by walking difficulties due to bilateral 
ankle contractures, impaired hearing, mild intellectual 
disability, and autism. As an adult, he was independent 
with regard to activities of daily living, with domestic 
assistance, and performed volunteer work for 2 days 
a week.
During a second episode, at age 44 years, he pre-
sented with abdominal pain, nausea, vomiting, and 
progressive asymmetrical weakness of both extrem-
ities. ADP was diagnosed based on increased urinary 
delta-aminolevulinic acid (ALA) levels, normal por-
phobilinogen levels, and low ALAD enzyme activity 
(10%-13% of the mean of normal). Lead poisoning, 
tyrosinemia, and other acute porphyrias were excluded. 
DNA sequencing detected two compound heterozy-
gous mutations in the ALAD gene (Supporting Fig. S1).
He was treated with heme arginate 250 mg 
(Normosang; Orphan Europe). Following recur-
ring attacks and disappointing recovery, prophylactic 
weekly heme therapy was initiated (plasma ALA then 
decreased to 1,977 nmol/L). The frequency of attacks 
decreased, but attacks still recurred. After several 
months, he developed resistant hypertension, and his 
neurological status slowly deteriorated with increasing 
weakness of all extremities, in parallel with a marked 
rise in plasma ALA (13,412 nmol/L).
A literature search on ADP was performed. 
Although ADP is considered a hepatic acute por-
phyria, there were more cases in which standard ther-
apy was not satisfactory.
Notably, Thunell et al.(2) reported on a boy in 
whom liver transplantation did not cure his ADP and 
 postulated that the disease might be erythroid in  origin. 
Also, the only late-onset case, of a Belgian patient, sup-
ported this hypothesis; he developed ADP due to a 
monoclonal erythroid disease,(3) polycythemia vera.
Abbreviations: ADP, delta-aminolevulinic acid dehydratase-porphyria; ALA, delta-aminolevulinic acid; ALAD, delta-aminolevulinic acid 
dehydratase.
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On top of weekly heme, we initiated weekly 
blood transfusions and hydroxycarbamide 1,000 
mg once daily, to reduce erythroid heme synthesis. 
Within 2 weeks, symptoms improved and blood 
pressure returned to normal. Three months later he 
was still improving. He has no abdominal pain or 
weaknesses. Plasma ALA dropped from 10,270 to 
3,298 nmol/L.
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taBle 1. Detailed Description of aDp Cases
Present Case Germany 1 Germany 2 Sweden Belgium Germany 3 USA Germany 4
Phenotype
Sex Male Male Male Male Male Male Male Male
Age at onset <1 year 15 years 15 years <1 year 63 years 15 years 12 years 7 years
Acute symptoms Abdominal pain Abdominal 
pain, 
vomiting, 
constipation
Pain in 
extremities, 
vomiting
Recurrent 
 abdominal 
pain, vomiting
n/a Abdominal 
pain
Abdominal 
pain, 
vomiting, 
constipation
Abdominal 
pain, 
vomiting, 
diarrhea
Motor  weakness 
(arms and/ 
or legs)
Yes Yes Yes Yes Yes n/a Yes No
Respiratory 
failure
Yes Yes Yes Yes No No No No
Therapeutic response
Response of 
symptoms to 
heme
Partial response* Partial 
response
Partial 
response
No response* No response to 
heme (some 
response to iv 
glucose)
Partial 
response*
Only 
initially good 
response*
n/a
Response of 
ALA to  
heme
~30% reduction 
but later raised 
despite continued 
treatment
~15% 
reduction, 
remained 
elevated
>50% 
reduction, 
remained 
elevated
~50% reduction
but later raised 
again despite 
continued 
treatment
~66% reduction 
of urinary ALA
~50% 
 reduction, 
ALA 
remains 
elevated
n/a n/a
Long-term 
follow-up
Progression of disease 
on heme therapy, 
improvement 
following blood 
transfusion and 
hydroxycarbamide 
(hydroxyurea)
Patient alive 
and well 25 
years later
Patient alive 
and well 
almost 30 
years later
No improvement 
after liver 
transplantation
Died from  
pneumonia at 
age 9 years
Died due to 
hematological 
malignancy 
(polycythemia 
vera)
n/a Significant 
continuing  
motor 
 weakness 
(wrists and 
ankles)
n/a
Full information (e.g., biochemical data, clinical details) on all cases and related references are presented in Supporting Table S1. 
Patients after the present case are presented in order of publication. Cases of special interest for the “erythroid overproduction” hypoth-
esis are in bold. All patients with ADP seem to have an unsatisfactory response to standard therapy for the acute porphyrias. Especially 
the failure of liver transplantation to cure a Swedish boy and the coinciding of ADP with a monoclonal erythroid disease in a 63-year-
old Belgian man support the hypothesis that overproduction of ALA can originate from both the liver and the bone marrow.
*Patient has received prophylactic heme treatment.
Abbreviations: iv, intravenous; n/a, not available.
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Summary of Case Series
Data and references from all cases are presented in 
Table 1 (see also Supporting Table S1).
All DNA-confirmed ADP patients were male. 
Seven patients experienced porphyric symptoms 
during childhood. Six patients presented with abdom-
inal pain, one with pain in his extremities. Only the 
late-onset patient presented with neuropathy of the 
extremities but no pain. Acute neuropathy was seen 
in various degrees in all patients, ranging from mus-
cle weakness to severe paralysis. Four patients with 
paralysis required mechanical ventilation for transient 
respiratory failure.
Seven patients were treated with glucose and/or 
heme for attacks. Heme treatment was partially effec-
tive at reducing acute attack symptoms; it reduced 
abdominal pain and stabilized neurological symptoms. 
Three patients with a partial response were given 
weekly infusions to prevent attacks. In all 3 patients 
urinary ALA levels remained elevated. Liver trans-
plantation had no effect in one case.
Discussion
We report on an ADP case with abdominal pain 
and progressive neurological symptoms despite pro-
phylactic heme therapy to reduce hepatic ALA pro-
duction. We demonstrate that these symptoms could be 
improved by also suppressing erythroid heme synthesis, 
through blood transfusions and hydroxycarbamide.
Patients with ADP seem to have a diminished 
response to standard therapy for acute hepatic por-
phyrias, despite hepatic 5′-aminolevulinate synthase 
1 mRNA being increased.(4) The failure of liver trans-
plantation to cure 1 patient and the late manifestation 
coinciding with a monoclonal myeloproliferative neo-
plasm support the hypothesis that in ADP patients 
ALA can also be overproduced by bone marrow. ADP 
appears to be an erythrohepatic porphyria.
Suppression of erythroid ALA by blood transfu-
sions and hydroxyurea may be considered, as reported 
here.
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